Vitamin D and Omega-3 Fatty Acids: study protocols
32 study groups took Vitamin D together with Omega-3 Fatty Acids. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Vitamin D
26 study groups in 25 studies say how much Vitamin D participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1,000 IU to 2,500 IU, 58% of 26 study groups.
| Daily dose | Study groups |
|---|---|
| 500 IU to 1,000 IU | 3 |
| 1,000 IU to 2,500 IU | 15 |
| 2,500 IU to 5,000 IU | 1 |
| 5,000 IU to 10,000 IU | 6 |
| over 10,000 IU | 1 |
Dose per serving from research: Omega-3 Fatty Acids
27 study groups in 26 studies say how much Omega-3 Fatty Acids participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 63% of 27 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 2 |
| 500 mg to 1 g | 17 |
| 1 g to 2.5 g | 6 |
| 2.5 g to 5 g | 1 |
| over 5 g | 1 |
Commonly used together
9 of 32 study groups took Vitamin D and Omega-3 Fatty Acids with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Fish Oil | 3 |
32 study groups
| Study | ||||
|---|---|---|---|---|
| Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial 2020 · juice-based TMN · Patients with non-small-cell lung cancer receiving first-line chemotherapy, with weight loss or low BMI | 20 mcg | 2 g | 12 weeks | 26 |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 2,000 IU | 840 mg | 1936 days | — |
| Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial 2020 · Vitamin D3 and marine omega-3 fatty acids active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry | 2,000 IU | 1 g | 1937 days | — |
| Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial 2022 · Vitamin D plus marine omega-3 supplementation (exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years | 2,000 IU | 1 g | 3 years | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes 2023 · combination supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population | 2,000 IU | 1 g | 1935 days | — |
| Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial 2024 · Vitamin D and n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses | 2,000 IU | 1 g | 1936 days | — |
| Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial 2025 · Vitamin D plus marine omega-3 · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults | 2,000 IU | 840 mg | 1935 days | — |
| Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial 2018 · TMN · Adults aged 50 years or older with moderate-to-severe COPD and pre-cachexia or cachexia | 20 mcg | 4 g | 12 weeks | 22 |
| The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial 2024 · group 3: both omega-3 and vitamin D supplementation (ω3+VitD) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment | 7,143 IU | 600 mg | 9 weeks | 24 |
| Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡) 2020 · vitamin D and omega-3 LCPUFA (VIDOM) · Children aged 2.5–8 years with autism spectrum disorder | 2,000 IU | 722 mg | 1 year | 15 |
| Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children 2018 · Group C · Children aged 7–15 with nocturnal enuresis | 1,000 IU | 1 g | 60 days | — |
| Low-Dose Omega-3 Fatty Acid and Vitamin D for Anthropometric, Biochemical Blood Indices and Respiratory Function. Does it work? 2020 · experimental group · Office workers aged 40–60 years; sex and health condition not stated | 5 mcg | 330 mg | 16 weeks | — |
| Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial 2023 · vitamin D plus omega-3 fatty acids · Men aged 50 and older without clinically apparent cardiovascular disease or cancer; this analysis excluded men with multiple sclerosis or Parkinson’s disease at baseline | 2,000 IU | — | 1935 days | — |
| The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial 2025 · ω3+VitD group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported | 7,143 IU | 600 mg | 9 weeks | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3 and omega-3s, without SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 2,000 IU | 1 g | 3 years | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3 and omega-3s with SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 2,000 IU | 1 g | 3 years | — |
| Effects of a 6-Month Multifaceted Diet and Exercise Intervention on Cognition in Older Adults at Risk of Cognitive Decline: The PONDER Double-Blind, Placebo-Controlled Randomized Trial 2022 · Multimodal exercise program with daily supplement · Community-dwelling older adults with subjective memory impairment; mean age 70.2 years, 70% female | 1,000 IU | 1.5 g | 26 weeks | 73 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 5 mcg | 600 mg | 120 days | 26 |
| The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study 2015 · Cholecalciferol with omega-3 FA group · Hemodialysis patients with baseline 25(OH)D levels below 30 ng/mL; mean age 62.1 years; 33.3% men | 7,143 IU | 2.4 g | 12 weeks | 8 |
| Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial 2023 · D+ group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified | 7,143 IU | 300 mg | 8 weeks | 47 |
| The effects of fish oil plus vitamin D(3) intervention on non-alcoholic fatty liver disease: a randomized controlled trial 2022 · FO + D group · Adults aged 56.0 ± 15.9 years with non-alcoholic fatty liver disease | 1,680 IU | 2.34 g | 90 days | 37 |
| Multiple Micronutrients, Lutein, and Docosahexaenoic Acid Supplementation during Lactation: A Randomized Controlled Trial 2020 · MMS group · Healthy breastfeeding women, aged 18–45 years, beginning supplementation 4–6 weeks after delivery | 600 IU | — | 12 weeks | 35 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 4,000 IU | 100 mg/kg | 6 weeks | 19 |
| The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners 2021 · ω-3 PUFA group · Healthy physically active male recreational marathon runners, with no stated disease; age range not reported | 30 mcg | 2.45 g | 3 weeks | 12 |
| Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients 2020 · cosupplementation group · Colorectal cancer patients | 7,143 IU | — | 8 weeks | — |
| Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial 2020 · n-3 LCPUFA plus vitamin D · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified | 2,400 IU | 2.4 g | 17 weeks | — |
| Effects of Vitamin D and Omega-3 Fatty Acids Co-Supplementation on Inflammatory Factors and Tumor Marker CEA in Colorectal Cancer Patients Undergoing Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2020 · co-supplementation · Patients with stage II or III colorectal cancer undergoing chemotherapy | 7,143 IU | — | 8 weeks | — |
| The effect of combined supplementation with vitamin D and omega-3 fatty acids on blood glucose and blood lipid levels in patients with gestational diabetes 2021 · test group · Women aged 18–40 with gestational diabetes | 80,000 IU | 16 g | 6 weeks | — |
| Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial 2022 · Vitamin D3 and marine n-3 fatty acids active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization | 2,000 IU | 1 g | 1935 days | — |
| Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial 2025 · Vitamin D3 plus marine n-3 fatty acids · Females aged 55 years or older and males aged 50 years or older; no specific condition stated | 2,000 IU | 1 g | 5 years | — |
| Multimicronutrient and omega-3 fatty acid supplementation reduces low-grade inflammation in older participants: An exploratory study 2025 · multimicronutrient and n-3 PUFA supplementation · Healthy, physically active older adults; mean age 75.6 ± 3.9 years; sex not specified | 50 mcg | 1 g | 12 weeks | — |
| Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial 2023 · Vitamin D3 plus marine omega-3s · Generally healthy, robust, community-dwelling adults aged 70 years or older | 2,000 IU | 1 g | 3 years | — |